1. Home
  2. SANA vs CRMD Comparison

SANA vs CRMD Comparison

Compare SANA & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sana Biotechnology Inc.

SANA

Sana Biotechnology Inc.

N/A

Current Price

$2.01

Market Cap

688.5M

Sector

Health Care

ML Signal

N/A

Logo CorMedix Inc.

CRMD

CorMedix Inc.

N/A

Current Price

$4.74

Market Cap

590.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SANA
CRMD
Founded
2018
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
688.5M
590.7M
IPO Year
2021
2009

Fundamental Metrics

Financial Performance
Metric
SANA
CRMD
Price
$2.01
$4.74
Analyst Decision
Strong Buy
Buy
Analyst Count
9
5
Target Price
$8.43
★ $15.60
AVG Volume (30 Days)
★ 2.6M
1.9M
Earning Date
11-05-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
17.24
★ 780.00
EPS
N/A
★ 0.57
Revenue
N/A
★ $311,709,000.00
Revenue This Year
N/A
$8.00
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$8.49
Revenue Growth
N/A
★ 617.03
52 Week Low
$2.00
$4.82
52 Week High
$5.49
$13.02

Technical Indicators

Market Signals
Indicator
SANA
CRMD
Relative Strength Index (RSI) 32.21 24.50
Support Level N/A N/A
Resistance Level $3.41 $8.79
Average True Range (ATR) 0.19 0.52
MACD -0.02 -0.16
Stochastic Oscillator 15.96 1.24

Price Performance

Historical Comparison
SANA
CRMD

About SANA Sana Biotechnology Inc.

Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.

About CRMD CorMedix Inc.

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.

Share on Social Networks: